Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial

This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). Stage IV NSCLC patients who had previously received platinum-doublet chemotherapy wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol-Kyu, Jun, Ha Ra, Oh, Hyung-Joo, Lee, Ji-Young, Cho, Hyun-Ju, Kim, Young-Chul, Lee, Jeong Eun, Yoon, Seong Hoon, Choi, Chang Min, Lee, Jae Cheol, Lee, Sung Yong, Lee, Shin Yup, Chun, Sung-Min, Oh, In-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177441/
https://www.ncbi.nlm.nih.gov/pubmed/37174645
http://dx.doi.org/10.3390/cells12091246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177441/
https://www.ncbi.nlm.nih.gov/pubmed/37174645
http://dx.doi.org/10.3390/cells12091246

Ejemplares similares